cyclophosphamide · Avyxa Holdings · NDA 210852
Frindovyx
Earliest generic entry, as listed · earliest of 3 marketed strengths
1 Dec 2035
Blocked by patent: US 11382923.
Listed patents · 2 unexpired
| Patent | Claims | Expires |
|---|---|---|
| US 11382923 | product | 1 Dec 2035 |
| US 10849916 | product | 13 Jul 2035 |
Exclusivities · 0 unexpired
No unexpired exclusivities listed.
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.
Products covered · 3
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 210852 · 001 · RLD | solution, intravenous | 500MG/ML (500MG/ML) | 1 Dec 2035 |
| 210852 · 002 · RLD | solution, intravenous | 1GM/2ML (500MG/ML) | 1 Dec 2035 |
| 210852 · 003 · RLD | solution, intravenous | 2GM/4ML (500MG/ML) | 1 Dec 2035 |